EMA Regulatory and procedural guideline: Public consultation concerning the physical attendance and the location of personal residency of the qualified person

May 19, 2022

The COVID-19 pandemic required manufacturers and importers of medicinal products and regulatory authorities to operate under business continuity mode, impacting the standard way of working. As a result it was necessary to publish guidance on regulatory expectations and flexibility during the COVID-19 pandemic to minimise risks of shortages while ensuring that the high standards of quality, safety and efficacy of medicines made available to patients in the EU were maintained. This guidance has been developed in cooperation between the European Commission, the Coordination group for Mutual recognition and Decentralised procedures – human (“CMDh”), the Inspectors Working Group, the Coordination group for Mutual recognition and Decentralised procedures – veterinary (“CMDv”) and EMA.

Download EMA Regulatory and procedural guideline

Interested in learning more? Contact us today to find out how we can help not only with your EMA/FDA submissions, but all of your global regulatory needs.

Agency Alerts General Regulatory

July 19, 2017

FDA Issues Draft Standardization of Pharmaceutical Quality/Chemistry Manufacturing and Control Data Elements and Terminologies, Requests Comments

On Tuesday, July 11th, FDA released its draft standardized Pharmaceutical Quality/Chemistry Manufacturing and Control (PQ/CMC) data elements and terminologies for the electronic submission of this...

Read the Full Article
Quality & Compliance GCP

October 26, 2016

#10: Investigator Responsibilities – Protecting the Rights, Safety, & Welfare of Study Subjects

In October 2009, the FDA issued a guidance document regarding its expectations for investigators during the conduct of clinical investigations.The guidance, entitled Investigator...

Read the Full Article

September 3, 2021

The Essential Guide to Local Person for Pharmacovigilance

Every marketing authorization holder (MAH) needs a pharmacovigilance system to guarantee the safety of its products. When setting up a pharmacovigilance system in Europe, the Qualified Person for...

Read the Full Article